Medadvisor Ltd (MDR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medadvisor Ltd (MDR) has a cash flow conversion efficiency ratio of 5.093x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-8.24 Million ≈ $-5.83 Million USD) by net assets (AU$-1.62 Million ≈ $-1.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medadvisor Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Medadvisor Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MDR total debt and obligations for a breakdown of total debt and financial obligations.
Medadvisor Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medadvisor Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Check-Cap Ltd
F:7CC
|
2.441x |
|
Saxlund Group AB
ST:SAXG
|
-0.028x |
|
Conduit Pharmaceuticals Inc.
NASDAQ:CDT
|
0.194x |
|
Euroland Corporate SA
PA:MLERO
|
N/A |
|
IZOTROPIC CORP.
F:1R3
|
0.029x |
|
Plasto-Cargal Group Ltd
TA:PLCR
|
0.066x |
|
Meta Epsi Tbk PT
JK:MTPS
|
0.244x |
|
Primeserv Group Ltd
JSE:PMV
|
0.041x |
Annual Cash Flow Conversion Efficiency for Medadvisor Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Medadvisor Ltd from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see MDR company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$-1.62 Million ≈ $-1.14 Million |
AU$-14.37 Million ≈ $-10.16 Million |
8.880x | +8729.14% |
| 2024-06-30 | AU$51.58 Million ≈ $36.50 Million |
AU$5.19 Million ≈ $3.67 Million |
0.101x | +435.19% |
| 2023-06-30 | AU$48.46 Million ≈ $34.29 Million |
AU$-1.45 Million ≈ $-1.03 Million |
-0.030x | -338.61% |
| 2022-06-30 | AU$34.55 Million ≈ $24.44 Million |
AU$-236.32K ≈ $-167.21K |
-0.007x | +97.34% |
| 2021-06-30 | AU$48.85 Million ≈ $34.56 Million |
AU$-12.54 Million ≈ $-8.88 Million |
-0.257x | +49.65% |
| 2020-06-30 | AU$17.02 Million ≈ $12.04 Million |
AU$-8.68 Million ≈ $-6.14 Million |
-0.510x | +36.52% |
| 2019-06-30 | AU$8.64 Million ≈ $6.12 Million |
AU$-6.95 Million ≈ $-4.91 Million |
-0.803x | -272.90% |
| 2018-06-30 | AU$15.17 Million ≈ $10.73 Million |
AU$-3.27 Million ≈ $-2.31 Million |
-0.215x | +16.19% |
| 2017-06-30 | AU$9.35 Million ≈ $6.62 Million |
AU$-2.40 Million ≈ $-1.70 Million |
-0.257x | +75.12% |
| 2016-06-30 | AU$2.46 Million ≈ $1.74 Million |
AU$-2.55 Million ≈ $-1.80 Million |
-1.033x | -123.13% |
| 2015-06-30 | AU$-106.88K ≈ $-75.63K |
AU$-477.40K ≈ $-337.79K |
4.467x | +155.67% |
| 2014-06-30 | AU$310.98K ≈ $220.04K |
AU$-2.50 Million ≈ $-1.77 Million |
-8.024x | -2576.88% |
| 2013-06-30 | AU$11.11 Million ≈ $7.86 Million |
AU$-3.33 Million ≈ $-2.36 Million |
-0.300x | -44.27% |
| 2012-06-30 | AU$2.78 Million ≈ $1.97 Million |
AU$-577.73K ≈ $-408.78K |
-0.208x | -5068.77% |
| 2011-06-30 | AU$3.14 Million ≈ $2.22 Million |
AU$-12.62K ≈ $-8.93K |
-0.004x | -- |
About Medadvisor Ltd
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anm… Read more